IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v6y2015i1d10.1038_ncomms9940.html
   My bibliography  Save this article

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Author

Listed:
  • Michal Kovac

    (Bone Tumour Reference Center at the Institute of Pathology, University Hospital Basel
    The Wellcome Trust Centre for Human Genetics, University of Oxford)

  • Claudia Blattmann

    (Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart Olgahospital
    Oncology, Immunology and Pulmology, University of Heidelberg)

  • Sebastian Ribi

    (Bone Tumour Reference Center at the Institute of Pathology, University Hospital Basel)

  • Jan Smida

    (Institute of Radiation Biology, Clinical Cooperation Group Osteosarcoma, Helmholtz Zentrum München
    Pediatric Oncology Center, Technische Universität München and Comprehensive Cancer Center)

  • Nikola S. Mueller

    (Institute of Computational Biology, Helmholtz Zentrum München)

  • Florian Engert

    (Institute for Experimental Cancer Research in Pediatrics, Goethe-University
    German Cancer Consortium (DKTK)
    German Cancer Research Center (DKFZ))

  • Francesc Castro-Giner

    (The Wellcome Trust Centre for Human Genetics, University of Oxford)

  • Joachim Weischenfeldt

    (European Molecular Biology Laboratory (EMBL), Genome Biology Unit)

  • Monika Kovacova

    (The Institute of Mathematics and Physics, Faculty of Mechanical Engineering, Slovak University of Technology)

  • Andreas Krieg

    (Basel University Childrens Hospital (UKBB))

  • Dimosthenis Andreou

    (Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch
    Present address: Department of General Orthopedics and Tumour Orthopedics, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149 Münster, Germany)

  • Per-Ulf Tunn

    (Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch)

  • Hans Roland Dürr

    (Ludwig-Maximilians-University Munich, Campus Grosshadern)

  • Hans Rechl

    (Clinic and Policlinic of Orthopedics and Sports Orthopedics, Technische Universität München)

  • Klaus-Dieter Schaser

    (University Hospital Dresden)

  • Ingo Melcher

    (Center for Musculoskeletal Surgery, Charité—University Medicine Berlin, Campus Virchow Klinikum)

  • Stefan Burdach

    (Pediatric Oncology Center, Technische Universität München and Comprehensive Cancer Center)

  • Andreas Kulozik

    (Oncology, Immunology and Pulmology, University of Heidelberg)

  • Katja Specht

    (Institute of Pathology, Technische Universität München)

  • Karl Heinimann

    (Medical Genetics, University Hospital Basel)

  • Simone Fulda

    (Institute for Experimental Cancer Research in Pediatrics, Goethe-University
    German Cancer Consortium (DKTK)
    German Cancer Research Center (DKFZ))

  • Stefan Bielack

    (Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart Olgahospital)

  • Gernot Jundt

    (Bone Tumour Reference Center at the Institute of Pathology, University Hospital Basel)

  • Ian Tomlinson

    (The Wellcome Trust Centre for Human Genetics, University of Oxford)

  • Jan O. Korbel

    (European Molecular Biology Laboratory (EMBL), Genome Biology Unit)

  • Michaela Nathrath

    (Institute of Radiation Biology, Clinical Cooperation Group Osteosarcoma, Helmholtz Zentrum München
    Pediatric Oncology Center, Technische Universität München and Comprehensive Cancer Center
    Klinikum Kassel)

  • Daniel Baumhoer

    (Bone Tumour Reference Center at the Institute of Pathology, University Hospital Basel)

Abstract

Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has historically complicated driver gene discovery. Here we sequence exomes of 31 tumours and decipher their evolutionary landscape by inferring clonality of the individual mutation events. Exome findings are interpreted in the context of mutation and SNP array data from a replication set of 92 tumours. We identify 14 genes as the main drivers, of which some were formerly unknown in the context of osteosarcoma. None of the drivers is clearly responsible for the majority of tumours and even TP53 mutations are frequently mapped into subclones. However, >80% of osteosarcomas exhibit a specific combination of single-base substitutions, LOH, or large-scale genome instability signatures characteristic of BRCA1/2-deficient tumours. Our findings imply that multiple oncogenic pathways drive chromosomal instability during osteosarcoma evolution and result in the acquisition of BRCA-like traits, which could be therapeutically exploited.

Suggested Citation

  • Michal Kovac & Claudia Blattmann & Sebastian Ribi & Jan Smida & Nikola S. Mueller & Florian Engert & Francesc Castro-Giner & Joachim Weischenfeldt & Monika Kovacova & Andreas Krieg & Dimosthenis Andre, 2015. "Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency," Nature Communications, Nature, vol. 6(1), pages 1-9, December.
  • Handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9940
    DOI: 10.1038/ncomms9940
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms9940
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/ncomms9940?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Yafei Jiang & Jinzeng Wang & Mengxiong Sun & Dongqing Zuo & Hongsheng Wang & Jiakang Shen & Wenyan Jiang & Haoran Mu & Xiaojun Ma & Fei Yin & Jun Lin & Chongren Wang & Shuting Yu & Lu Jiang & Gang Lv , 2022. "Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    2. Georgia Zoumpoulidou & Carlos Alvarez-Mendoza & Caterina Mancusi & Ritika-Mahmuda Ahmed & Milly Denman & Christopher D. Steele & Maxime Tarabichi & Errin Roy & Lauren R. Davies & Jiten Manji & Camilla, 2021. "Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma," Nature Communications, Nature, vol. 12(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9940. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.